Keyword: CMI0324

Chemistry & Life Sciences

Expert Statement: Neil Jones, Aenova

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Federico Pollano, Rentschler

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Victor Swint, Formulated Solutions

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Ashu Tandon, Aragen

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Davuluri Saharsh Rao, Neuland Labs

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Martin Meeson, Axplora

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Torsten Wöhr, Bachem

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Chemistry & Life Sciences

Expert Statement: Tom Wilson, Pfizer

02.09.2024 -

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.